About AST Products
AST Products, Inc. was founded in 1989 to develop novel surface technologies and coatings. Initially a research based organization, AST now develops and manufactures ophthalmic medical devices as well as a line of patented and proprietary coatings for the medical device and specialty materials industries. AST also provides specially engineered plasma reactors and analysis equipment that facilitate the application of its advanced coatings.
Headquartered in Billerica, Massachusetts, AST operates a 23,000 square foot facility fully equipped with Class 10,000 and Class 100,000 cleanrooms, and advanced analytical and research labs. As an ISO 13485:2003 registered business, AST can offer contract surface treatment services to companies that require the highest degree of quality from their suppliers.
Partnership Approach
AST understands that its customers expect a committed partner. Accordingly, AST collaborates with its customers from beginning to end. Our customers enjoy complete access to AST’s considerable technical expertise throughout the design and development process. By working with customers every step of the way, small design changes can be made early in the process. This prevents huge delays and overruns late in the game. Our partnership support does not end with the finalization of coating formulation or product design. We work with the customers to ensure smooth and trouble-free implementation at their or at AST’s facilities. Additionally, AST’s experienced staff continues to provide assistance throughout any approval or installation process.
A memorable day of the 1st implantation of our advanced monofocal IOL by Dr. Ignacio Lopez-Marin Espigares of VISIÓON Oftalmólogos. Thank you so much for trusting in us. Making Happy Patients, One by One!
Today (February 26, 2025), we are very excited to receive the good news to announce another publication of the 9th peer-reviewed technical paper on our Asqelio™ EDOF IOL in the Frontiers in Medicine, Sec. Ophthalmology (2025, v12:1513803). The paper is now available as open access via the link below.
This study aims to evaluate refractive, visual, and patient-reported outcomes three months after bilateral implantation of a novel bi-aspheric, non-diffractive extended depth of focus (EDOF) intraocular lens (IOL) using Phase-Ring™ technology to achieve good vision across distances with reduced dysphotopsia.
The study concluded that Asqelio™ EDOF IOL offers an efficient design, providing good clinical outcomes for distance and intermediate vision, while some patients reach functional levels of near vision. Its non-diffractive design minimizes dysphotopsia and reduces light distortion compared to other presbyopia-correcting IOLs.
Many thanks to all team members, doctors, the hospital that had contributed and collaborated on this study. The result certainly has further convinced and encouraged us to progressively move forward and to ‘Making Happy Patients, One-by-One'.
https://lnkd.in/eGkXuX6A
Are you looking for a fresh new perspective on the IOL industry?
Join the European Federation of the Contact Lens and IOL Industries (EFCLIN) in Oslo, Norway!
At the EFCLIN Congress, it's your opportunity to connect with industry leading organizations from around the globe, in a tight-knit community setting. With thought-provoking keynote sessions, cutting edge product showcases, and invaluable networking opportunities, it's the event that you don't want to miss!
Click below to secure your spot today and take advantage of early-bird registration rates!
Today (December 31, 2024), we are very excited to receive the very last good news of the year and to announce another publication of the 8th peer-reviewed technical paper on our Asqelio™ Monofocal IOL in the Journal of Ophthalmology (2024, Article ID 3520219). The paper is now available as open access via the link below.
This study aims to analyze the prevalence and severity of posterior capsule opacification (PCO) and glistening in a new hydrophobic bi-aspheric monofocal intraocular lens (IOLs) 24 months after implantation.
The study concluded that prevalence of PCO was considerably lower for Asqelio IOL than for the Control IOL and reports available in the literature for other hydrophobic IOLs. Prevalence of glistening was minimal in both study and control IOLs.
Many thanks to all team members, doctors, the hospital that had contributed and collaborated on this study. The result certainly has further convinced and encouraged us to progressively move forward and to ‘Making Happy Patients, One-by-One'.
https://lnkd.in/eF85kuDPhttps://lnkd.in/eAvdxk7Z#astproducts#astvisioncare#asqelio#IOL#IOLs#cataractsurgery#refractivesurgery
We hope this greeting brings a smile to your face and reminds you how much we value one by one.
Wishing you and your loved ones a wonderful holiday season and a prosperous New Year.
Warmest Regards,
AST VisionCare Group
December 20, 2024
Final day of our exhibition at the 2024 AAO (American Academy of Ophthalmology) Annual Meeting from October 19 to 21, 2024.
Venue: McCormick Place, Chicago.
Please visit us at booth #2129.
#AAO2024
2nd day of our exhibition at the 2024 AAO (American Academy of Ophthalmology) Annual Meeting from October 19 to 21, 2024.
Venue: McCormick Place, Chicago.
Please visit us at booth #2129.
#AAO2024
We are exhibiting at the 2024 AAO (American Academy of Ophthalmology) Annual Meeting from October 19 to 21, 2024.
Venue: McCormick Place, Chicago.
Please visit us at booth #2129.
#AAO2024
The '5 Years of Asqelio' roundtable event at ESCRS 2024 on September 6 in the evening at the Hotel Miramar Barcelona has become a memorable occasion. We are grateful to all the doctors who have placed their trust in us and acknowledge the unwavering support of our European colleagues who have championed our Asqelio series of IOLs.
https://lnkd.in/eTsnSGyV
